iCAD Dividendi e riacquisti

Dividendo criteri di controllo 0/6

iCAD non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-0.3%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-0.3%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Looks Just Right With A 47% Price Jump

Nov 09

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Aug 21

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

Jun 27

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ICAD siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ICAD siano aumentati.

Rendimento dei dividendi rispetto al mercato

iCAD Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ICAD rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ICAD)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Healthcare Services)	0.9%
Analista previsionale (ICAD) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ICAD rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ICAD rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ICAD per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ICAD non ha segnalato alcun pagamento.

iCAD Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.24 loss, revenue downgraded

iCAD, Inc.'s ProFound Detection Version 4.0 Gains FDA Clearance

iCAD, Inc. (NASDAQ:ICAD) Looks Just Right With A 47% Price Jump

iCAD, Inc. to Report Q3, 2024 Results on Nov 13, 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus EPS estimates fall by 18%, revenue upgraded

New major risk - Revenue and earnings growth

iCAD, Inc. to Report Q2, 2024 Results on Aug 13, 2024

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

iCAD, Inc. to Report Q1, 2024 Results on May 15, 2024

iCAD, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD, Inc. to Report Q4, 2021 Results on Feb 28, 2022